Movin (Cinnarizine, Dimenhydrinate)

Cinnarizine blocks calcium channels and antagonizes H1 histamine receptors, reducing inner‑ear excitability. Dimenhydrinate also blocks H1 receptors and adds anticholinergic activity, dampening vestibular signals to the brain. Together they provide a synergistic effect that lessens dizziness and the urge to vomit.

The specific dose of Movin is determined by the prescribing clinician based on the patient’s age, weight, severity of symptoms and medical history. Dosage instructions are provided on the prescription label and should be followed exactly as directed.

Safety data for cinnarizine and dimenhydrinate in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any possible risk to the fetus or infant, and this decision must be made by a qualified health professional.

To request Movin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with single‑ingredient antihistamines such as meclizine, Movin combines two agents that target both histamine receptors and calcium channels, offering broader symptom control. It may provide faster relief for severe vertigo, but individual response varies and clinicians choose therapy based on patient profile.

Store Movin at room temperature, preferably below 25 °C. Keep the tablets in the original blister pack, protect them from moisture, heat and direct sunlight to maintain potency throughout the shelf life.

Movin is taken orally with a glass of water. It can be taken with or without food, but patients should follow the prescribing information regarding timing relative to travel or onset of symptoms.

Serious risks include extrapyramidal reactions such as tremor or rigidity, severe allergic responses (anaphylaxis), and cardiac arrhythmias. Patients should seek immediate medical attention if they experience muscle stiffness, difficulty breathing, rash, or irregular heartbeats.

Movin is contraindicated in individuals with known hypersensitivity to cinnarizine, dimenhydrinate or any component of the formulation. It should also be avoided in patients with severe Parkinsonian disease, uncontrolled epilepsy, or those taking interacting CNS depressants without medical supervision.